Acute poisoning from opioid overdose

Acute poisoning from opioid overdose is the book’s starkest measure of a crisis that grows faster than the systems meant to contain it. The account links individual emergencies and mounting death counts to the wider conditions that shape who is exposed to opioids, who can obtain treatment, and whose suffering institutions recognize.

Scale and Changing Patterns

In southwest Virginia, the early rise was visible in a small but sharply increasing count: the Roanoke medical examiner recorded one OxyContin death in 1997, three in 1998, and sixteen in 1999. Those figures remained out of public view until 2001, five years after Purdue launched the drug. Officials and the company did not treat the emerging reports as evidence of a crisis spreading beyond the region; a Drug Enforcement Administration official described southwest Virginia as unusual, while Purdue Pharma declined to discuss illicit use of its medication.

By March 2001, the local toll had become harder to dismiss. Forty-three people in the region had died of oxycodone overdose since Purdue’s launch. At the Lee County jail, seventy-nine people were held in space designed for thirty-four, and drug use had shifted from snorting crushed tablets to injecting them with livestock syringes. The crisis also appeared in crimes undertaken to obtain OxyContin: a masked robber killed the manager of a Coeburn supermarket during an attempted robbery, and in Clintwood a man broke into a pharmacy and fled with pill bottles. These events registered the spread of overdose risk beyond medical settings, into households, jails, stores, and local public safety.

The danger continued to change as the drug supply changed. A batch containing carfentanil, an elephant sedative described as one hundred times stronger than fentanyl, was expected to cause twenty-six overdose cases in a single day in Huntington, West Virginia. The substance had been imported from China, while the state’s indigent burial-assistance program was approaching exhaustion for the fifth consecutive year. The episode places a local emergency within a supply chain capable of delivering a highly potent synthetic opioid into a community far from its source.

The national figures make that escalation still clearer. Overdose had already claimed 300,000 American lives over fifteen years, and experts projected that another 300,000 could die in the following five. It had become the leading cause of death for Americans under fifty, exceeding deaths from guns and car accidents and surpassing the rate of the HIV epidemic at its peak. The book sets these estimates against the daily, less countable burden carried by bereaved relatives and by the people trying to respond to the crisis.

Economic Conditions and Exposure

The account does not treat overdose as a consequence of individual drug use alone. In Martinsville, Virginia, and surrounding Henry County in Virginia, unemployment rose above 20 percent as manufacturing and other work declined. Food-stamp claims more than tripled, while disability rates increased by 60.4 percent. These figures describe communities where the loss of work was accompanied by shrinking household resources and fewer reliable routes to stability.

The book connects that economic deterioration to the expansion of opioid supply. Its account of the Opioid epidemic identifies the collapse of work and the rise in disability as conditions that heightened vulnerability, while pharmaceutical promotion and successive regulatory approvals increased access to painkillers. The relationship is presented as a convergence rather than a single cause: economic distress could deepen insecurity, while widespread opioid availability supplied a potent means of exposure. The book also notes that declining workforce participation was not confined to rural areas, though it was less severe where opioid prescribing was lower and college graduation rates higher.

These conditions also shaped whether people could obtain medical care before a crisis became acute. Virginia’s repeated rejection of Medicaid expansion meant forfeiting $6.6 million a day in federal funds and coverage for 400,000 low-income residents. In states that expanded Medicaid, the program paid for treatment, counseling, and addiction medication, including for people too poor for private insurance but not eligible under older Medicaid rules. The contrast makes insurance policy part of the practical story of survival: care that exists in principle may remain unreachable when people lack coverage or money for appointments.

A teacher’s circumstances show what that gap looked like in everyday life. She had been without insurance for decades, apart from a period when she qualified for Medicaid while pregnant. Her husband, formerly a Walmart worker and disabled by strokes, received Medicare. Without Virginia’s Medicaid expansion, she pieced together free coverage at Remote Area Medical events and occasional visits to the Health Wagon mobile unit. She avoided her family doctor except when she was nearly dying, since even a discounted cash visit cost $63. The example connects the state-level coverage dispute to delayed care and the narrow, improvised safety net available to an uninsured household.

Unequal Burdens of Prescribing and Punishment

The book also emphasizes that exposure to opioids and the consequences of drug enforcement were not distributed evenly. In Roanoke, heroin had once been treated as an isolated, largely invisible problem associated with a small group of mostly African American users and dealers. This history matters alongside the later expansion of prescription opioids: in data discussed by the book, doctors prescribed painkillers to people of color at substantially lower rates than to white patients, while young white people’s overdose death rate in 2014 was three times its 2002 level and the rate for people of color was relatively unchanged. The account presents those patterns as evidence of racialized differences in access to medication and risk, not as differences in inherent susceptibility.

Punishment followed a different racial pattern. The book contrasts broad appeals to alternatives to arrest, often made in response to white opioid users’ involvement in drug-related or property crime, with the continued imprisonment of Black and brown people for drug distribution. Three-quarters of federal drug offenders were Black or Hispanic, and people of color made up 57 percent of those imprisoned for drug offenses in state systems. The account further observes that drug-involved offenders constituted half the incarcerated population and had a 75 percent recidivism rate. Overdose is therefore set within a wider institutional disparity: some people encountered opioids through medical prescribing and were described as patients, while others were more readily encountered through policing and incarceration.

Treatment, Barriers, and Responses

The barriers continue after someone seeks help. Kristi Fernandez had previously sent her son, Jesse Bolstridge, to a ten-week treatment program in Jacksonville, Florida, involving counseling and medical detox. He briefly received buprenorphine, but was weaned off it after three weeks. Despite insurance, the stay left him with a $25,000 debt, which he was paying down at $25 a week through automatic withdrawals. His experience illustrates how a treatment episode could be costly and brief even when it included medication intended to reduce cravings.

Tess Henry’s care shows how financial resources and pregnancy affected treatment options. After leaving jail while nearly seven months pregnant, she spent a month with her mother and then entered the Life Center of Galax, one of the few Virginia facilities that accepted patients receiving medication-assisted treatment. Private insurance covered most of the $20,000 cost, while her father paid the $6,500 deductible from what remained of her college savings. She took Subutex, a buprenorphine medication then recommended for some pregnant patients. The book records the considerable expense and the role of family support without claiming that access to treatment removed the risk or uncertainty surrounding her recovery.

Even ongoing medication could bring substantial costs and delays. Insurance covered 80 percent of Tess’s buprenorphine, but her addiction doctor required $700 up front and $90 to $100 for each follow-up visit, with as many as four visits in a month. Patients also faced waiting lists. At the time, federal rules limited certified prescribers to 100 patients each; the cap later rose to 275. These constraints show how effective medication could be available yet difficult to sustain when provider capacity, cash-only practices, and the frequency of required visits narrowed access.

Roanoke’s Hope Initiative tried to make the fragmented system navigable. Its volunteers assembled a five-page spreadsheet of thirty-six rehabilitation and aftercare providers across the southeastern United States, using patients’ finances and available beds to guide referrals. At a monthly drop-in at the Bradley Free Clinic, people without outstanding warrants could be paired with trained volunteers to work through care options, while social-service workers helped eligible visitors apply for Medicaid. Some volunteers arranged outpatient medication-assisted treatment, although the group was divided over its use despite scientific evidence supporting it. The spreadsheet and the eligibility condition reveal both the practical labor of connecting people with care and the limits imposed by a system in which beds, insurance, and institutional beliefs all mattered.

Later efforts sought to reduce the gap between overdose treatment and continuing care. The Virginia Tech Carilion Research Institute received a $1 million grant to pilot protocols linking patients treated in emergency rooms directly to outpatient buprenorphine, including through the newly approved once-monthly injection Sublocade. Yet access remained limited: the Roanoke Community Services Board had added treatment for twenty-one patients only if they first engaged in counseling, and Carilion Clinic still had a three-week wait for outpatient medication-assisted treatment. The contrast between a new transfer model and those local bottlenecks captures the book’s central concern: preventing deaths requires more than recognizing overdose as an emergency. It requires treatment capacity, affordable follow-up, insurance, and community resources that remain available after the immediate crisis has passed.